TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01011842

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Standard of care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Align RT
Description: Standard of care
Study: NCT00304356

Intervention type: DRUG
Group type: OTHER
Intervention: Nitazoxanide
Description: 500 mg bid
Study: NCT02570061

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telephone
Description: information given at the primary contact by phone, or at a scheduled later time

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: consultation face-to-face
Description: information given at a scheduled consultation at the hospital
Study: NCT03316885

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clareon® IOL
Description: Foldable, single-piece posterior chamber IOL intended for long-term use over the lifetime of the cataract patient. This device is CE-marked (European Conformity) in the countries with participating Investigators.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract Surgery
Description: Routine small incision cataract surgery with unilateral IOL implantation
Study: NCT01820754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Neoadjuvant (Pre-Surgery): Cycles 2 and 3: Ipilimumab 10 mg/kg IV over 90 minutes~Adjuvant (Post-Surgery): Ipilimumab 10 mg/kg IV every 3 weeks times 2 doses beginning 4 weeks postoperative ( up to 10 weeks if needed for recovery)~Maintenance: Ipilimumab 10 mg/kg/IV every 12 weeks times 2 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel, Cisplatin, Carboplatin
Description: Neoadjuvant (Pre-Surgery) Cycle 1: Paclitaxel 175 mg/m2 IV over 3 hours , followed by Cisplatin 75 mg/m2 IV over 60 minutes or carboplatin AUC 6 IV over 30-60 minutes on day 1(Every 21 days x 1 cycle)~Cycles 2 and 3: Ipilimumab 10 mg/kg IV over 90 minutes, Paclitaxel 175 mg/m2 IV over 3 hours , followed by Cisplatin 75 mg/m2 IV over 60 minutes or carboplatin AUC 6 IV over 30-60 minutes on day 1(Every 21 days x 2 cycles)
Study: NCT01603446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Arginine
Description: NOW® L-Arginine powder
Study: NCT00853554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone Hydrochloride tablet 8 mg
Description: Hydromorphone Hydrochloride tablet 8 mg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dilaudid® tablet 8 mg
Description: Dilaudid® tablet 8 mg, single dose fasting
Study: NCT04535791

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cholecalciferol
Description: 4,000 IU orally daily for 30 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: 4,000 IU orally daily for 30 days
Study: NCT02456610

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMV/EBV specific CTLs
Description: Patients will receive approximately 1x10e6 CTLs/kg as a single infusion via IV injection and may receive 1 to 8 additional infusions at intervals of one week.
Study: NCT03414463

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TREAT
Description: A 4-week one-to-one intervention between the clinical RA (cRA) and participant. Comprised of eight sessions, it involves psycho-educational lessons and skill-building exercises to achieve objectives based on the characteristics of alexithymia.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TREAT
Description: A 4-week one-to-one intervention between the clinical RA (cRA) and participant. Comprised of eight sessions, it involves psycho-educational lessons and skill-building exercises to achieve objectives based on the characteristics of alexithymia.
Study: NCT03062956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MYK-491 or placebo
Description: Oral suspension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MYK-491 or placebo
Description: Oral suspension
Study: NCT01900028

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic sampling
Description: Blood samples taken pre and post dosing with olaparib+/- itraconazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib tablet dosing
Description: Olaparib tablets: Part A 100mg od, days 1 and 9 only. Part B 10x300mg doses over 5 days (300mg bd).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole 200mg od Part A days 5 to 11 only
Study: NCT02037542

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet and exercise
Description: Upon enrollment, the patient will be asked to meet with a dietitian to assess the individual patient's current diet and exercise routines. In the first session, the dietitian will provide individual counseling and together with the patient devise weight loss / exercise strategies that fit the patients' lifestyle. Following the initial assessment, patients will embark on a weekly program, with weekly meetings lasting 30min - 1h. Patients will be asked to record meal portions weekly in a Food Log (Appendix B), according to the established goal. At each meeting, the dietitian will review the Food Log with the patient and evaluate progress.
Study: NCT03338062

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Hepatobiliary Iminodiacetic Acid (HIDA) scan
Description: HIDA scan was used as the planning scan for SBRT.
Study: NCT02872779

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling for free mutant DNA analysis
Description: Blood sampling for Patients Treated for Metastatic Colorectal cancer
Study: NCT01682590

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Renal Remplacement Therapy
Description: Investigators of each center will have the choice of the RRT technique based on their usual practice: intermittent hemodialysis, intermittent hemodiafiltration, continuous hemodialysis, continuous hemofiltration, continuous hemodiafiltration (typically the continuous techniques in the acute phase, followed by intermittent techniques after stabilization).~In case of life threatening conditions within the 48 hours after randomisation (hyperkalemia, metabolic acidosis or pulmonary edema) the RRT will be initiated as soon as possible.~In case of improvement of renal function within the 48 hours after randomisation (defined as the return of spontaneous urine output \> 1000ml/24 hr or \>2000ml/24hr with diuretics), RRT is not mandatory.
Study: NCT02598388

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One 0.5 mL IM injection of 0.9 percent (%) saline.
Study: NCT00372814

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Home-Based Family Therapy
Description: Multisystemic Therapy (MST): Adolescents receiving MST will receive home-based, family psychotherapy sessions 2-3 times a week, lasting 60 minutes in duration from a pediatric mental health worker for six months. The purpose of the therapy sessions are to improve the youths' ability to complete their dilay diabetes illness management tasks, reduce average blood glucose levels and improve metabolic control.
Study: NCT04020042

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound image guidance
Description: Epidural landmarks will be determined with using ultrasound image
Study: NCT01682590

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal Remplacement Therapy
Description: Investigators of each center will have the choice of the RRT technique based on their usual practice: intermittent hemodialysis, intermittent hemodiafiltration, continuous hemodialysis, continuous hemofiltration, continuous hemodiafiltration (typically the continuous techniques in the acute phase, followed by intermittent techniques after stabilization).~In case of life threatening conditions within the 48 hours after randomisation (hyperkalemia, metabolic acidosis or pulmonary edema) the RRT will be initiated as soon as possible.~In case of improvement of renal function within the 48 hours after randomisation (defined as the return of spontaneous urine output \> 1000ml/24 hr or \>2000ml/24hr with diuretics), RRT is not mandatory.
Study: NCT03221920

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very Low Carbohydrate Diet
Description: 1 : 4 ratio of carbohydrate to fat of the total daily calories intake
Study: NCT04020042

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Landmark palpation
Description: Epidural landmarks will be determined with palpation
Study: NCT01363973

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VITALSTIM transcutaneous electrical stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VITALSTIM transcutaneous electrical stimulation
Study: NCT03485976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Treatment at the FDA-approved psoriasis dosing
Study: NCT00113321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: 20 mg/m2 IV over 1 hour daily x 5 days.
Study: NCT02146573

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continuity Care Intensivist Communication Training
Description: Physicians enrolled in the intervention arm will complete a two to three part communication training. Survey measures of communication competency and burnout will be administered at baseline, after training, and at the end of the study. After the communication training, physicians will undergo an OSCE assessment with a simulated patient to evaluate communication skills. At the end of the study, CCI providers will receive surveys that assess the experience and challenges of the role, repeat surveys assessing competency with communication and frequency of engaging families in goals of care conversations, in addition to a follow-up focus group that will assess their experience with the intervention, the time required and the potential tradeoffs in other duties required by them to participate as a CCI.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continuity Care Intensivist (CCI) Provider Program
Description: After undergoing CCI training, CCI providers will fulfill a standardized role with parent-patient dyads:~* CCI will meet with families on a regular basis and at change of physician of record throughout their entire PICU hospitalization.~* Help patients/families navigate decisions in concert with preferences and beliefs~* Help patients/families and other care providers look at bigger picture; trajectory of illness, goals, and hopes for the patient.~* Serve as point person for active intensivists on service and other specialists~* Help resolve conflict when multiple providers have different opinions on course of action
Study: NCT01527279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antazoline
Description: Patients assigned to antazoline group will be administered antazoline in boluses of 50mg diluted to 10cm3 every 5 minutes up to cumulative dose of 250mg or conversion of AF to SN. Drug administration will also be stopped in case of serious adverse event or conversion of AF to different supraventricular arrhythmia. BP will be measured before every injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: Patients assigned to control group will be administered 0.9% saline in boluses of 10cm3 every 5 minutes up to cumulative volume of 50cm3, conversion of AF to SN or in case of serious adverse event or conversion of AF to different supraventricular arrhythmia. BP will be measured before every injection.
Study: NCT01148602

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LED stopwatch-clock timers
Description: We will attach a large, in-your-face red LED stopwatch-clock timers to the patient's stretcher at the moment of ED arrival to act as a constant visual reminder to all team members (physicians, RN's, CT technologists) of the urgency of the situation.
Study: NCT02486042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omegaven
Description: Infants will receive nutritional supplementation with omega-3 fatty acids (omegaven).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard lipids (primarily omega-6 fatty acids)
Description: Infants will receive nutritional supplementation with standard intralipid, composed primarily of omega-6 fatty acids.
Study: NCT03304847

Intervention type: OTHER
Group type: OTHER
Intervention: ablation
Description: radio-frequency applications on arrhythmogenic substrate
Study: NCT01487590

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture moxibustion
Description: Six interventions with acupuncture moxibustion, stimulating point BL67, during 20 minutes each, 48 hours apart.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Six interventions with placebo (inactivated laser), stimulating point BL67, during 20 minutes each, 48 hours apart
Study: NCT02208609

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Day 1: Maize Tortillas with 20% Amaranth
Description: Subjects received Maize tortillas with 20% Amaranth added.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Day 2 Maize Tortillas without 20% Amaranth
Description: Maize tortillas without Amaranth.
Study: NCT00271947

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Transplantation
Description: Autologous Stem Cell Transplantation will be performed after conditioning regimen
Study: NCT02120794

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 530G Insulin pump
Description: Subjects will use 530G insulin pump with Threshold Suspend (TS) feature for one year.
Study: NCT04164979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT00352846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Description: 4 mg/m\^2 by vein over 30 Minutes at baseline and 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 400 mg by mouth daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 400 mg by mouth daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Carbonate
Description: 1200 mg by mouth daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Carbonate
Description: 1200 mg by mouth daily
Study: NCT01886183

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Training
Description: The participants of the study will be trained 8 balance games during 14 sessions
Study: NCT03507998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGX1321
Description: CGX1321 capsules for oral administration
Study: NCT00372814

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Telephone Calls
Description: Telephone Support Calls: Adolescents receiving TS will receive weekly 30 minute phone calls from a pediatric mental health worker for six months. The purpose of the call is to provide emotional support regarding the adolescent's chronic medical condition, assess adherence to the prescribed regimen and to help the adolescent brainstorm solutions to any barriers they identify to completion of diabetes care.
Study: NCT02056925

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Echocardiography
Study: NCT01123200

Intervention type: DEVICE
Group type: OTHER
Intervention: Brain Computer Interface for Wheelchair Tilt Control
Description: Patients will be given the BCI for use in-home, as long as they use the BCI at least 10 hours per week and complete monthly performance assessment sessions.
Study: NCT03143036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab, thalidomide and dexamethasone
Description: Patients will be treated with with the following schedule. IV daratumumab 16mg/kg body weight weekly for weeks 1-8 followed by daratumumab 16mg/kg body weight once every 2 weeks from weeks 9 to 24 and then daratumumab 16mg/kg once every 4 weeks from weeks 25 onwards until disease progression; PO thalidomide 100mg daily for 1 year and PO Dexamethasone 40mg (starting dose of dexamethasone is 20mg once weekly for patients \>75 years old) once weekly for 1 year (13 cycles, each cycle is 4 weeks). After 1 year, patient only continue on daratumumab until progression~Patients will be assessed every 28 days (+/-10 days).
Study: NCT04253665

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nursing discharge teaching
Description: Nurses will provide multimorbid seniors inpatients with teaching related to self-management to prepare them to be discharged home. The teaching delivery will be tailored to patients' activation level and priorities. The intervention begins by determining the level of activation at which patients are and identifying priorities to address related to patients' life situation. A Discharge Teaching Guide will be used by nurses to deliver the teaching and includes six domains of self-management. For each domain, nurses first report whether a priority has been identified and what intervention they have proposed to address it. Then for each domain, teaching objectives are described and differ according to the level of patient activation. These six domains of self-management are found in the patient-oriented discharge summary, which is a document for the patient that summarizes what has been addressed in discharge teaching.
Study: NCT03704714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT02634502

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Study: NCT03002714

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Study: NCT03296150

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRESTAGE
Description: PRESTAGE educational program targets the acquisition by the patients and their caregivers of competencies in (1) a better understanding of their disease and (2) their treatment, (3) a better drug management, including both anticancer and supportive treatments, (4) maintenance of a good nutritional status, (5) general health and psychological well being and (6) physical well being. After an individual educational diagnosis, each patient will be proposed an individualized educational program consisting in 1 to 6 of these workshops. An individualized final interview - entitled educational synthesis - will assess patient's skills and satisfaction.
Study: NCT04870372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selegiline
Description: Subjects will receive one Selegiline tablet (5 mg) per day administered at breakfast. The initial dose of Selegiline is 5 mg/day and be up-titrated in 2-week intervals in increments of 5 mg up to 10 mg (which can be taken at breakfast or divided doses of 5 mg each taken at breakfast and lunch) according to the investigator's judgment, based on individual clinical response and tolerability.
Study: NCT01320202

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Soluble Ferric Pyrophosphate (SFP)
Description: Patients to receive 11 micrograms (µg) of iron/ deciliter (dL) of dialysate during dialysis 3 or 4 times/week for up to 18 months.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Standard dialysate
Description: Patients to receive standard dialysate (no iron) during dialysis 3 or 4 times/week.
Study: NCT02629003

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [11C]Cimbi-36

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [11C]Cimbi-36-5
Study: NCT01794676

Intervention type: GENETIC
Intervention: Blood draw
Description: Blood draw

Intervention type: GENETIC
Intervention: Blood draw
Description: Blood draw
Study: NCT01886183

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Patients of the control group will be trained with balance exercises.
Study: NCT03075917

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self Questionnaire
Description: self questionnaire for allergic rhinitis control
Study: NCT04121260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Participants will receive dose 1 daratumumab with 30,000 U (2000 U/mL) with rHuPH20 SC injection.
Study: NCT04085198

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Light physics enhanced 'no-touch' hysteroscopy
Description: The light source used in hysteroscopy provides an illumined environment during the imagination with these techniques. During hysteroscopy, the light reflecting from the adjacent tissue appears bright, however, this reflection is weaker in farther tissue and these structures appear dark. This information will be used in determining the route from the vaginal introitus to the uterine cavity during the hysteroscopy.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard hysteroscopy
Description: Anatomical structures as illumined by the light source of the camera will be used to find the route from the vaginal introitus to the uterine cavity
Study: NCT02233244

Intervention type: DRUG
Group type: OTHER
Intervention: CTX-4430

Intervention type: DRUG
Group type: OTHER
Intervention: Midazolam
Study: NCT01218555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide (10mg, 15mg, 20mg or 25mg) once daily by mouth, every day of each 28-day cycle.
Study: NCT01794676

Intervention type: GENETIC
Intervention: Blood draw
Description: Blood draw
Study: NCT02513472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate
Description: Eribulin Mesylate will be administered as a 1.4 milligram per square meter (mg/m\^2) IV (intravenous) infusion on Day 1 and Day 8 of each 21-day cycle in the presence of clinical benefit until intercurrent illness, unacceptable toxicity, or disease progression occurs, or until the participant withdraws consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered as a 200 milligram (mg) IV infusion on Day 1 of each 21-day cycle in the presence of clinical benefit until intercurrent illness, unacceptable toxicity, or disease progression occurs, or until the participant withdraws consent.
Study: NCT00671606

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative Lymphatic Mapping
Description: Intraoperative hysteroscopic injection of patent blue dye and radiocolloid for detection of sentinel lymph nodes.